论文部分内容阅读
2010年6月10日,印度科学和工业研究委员会(CSIR)在欧洲专利局(EPO)审理的专利异议诉讼中,取得胜利,成功驳回一项药物专利申请的授权。该专利的申请人是中国最著名的医药研发、制造企业之一,涉案专利申请于2007年,获得EPO授权之后的9个月异议期内,该专利申请被CSIR提出异议,异议人认为:相关药物成份在公元前1500多年就已经在印度使用,公元9世纪的发表证据可以证明印度已经公开使用相关技术,因此来自中国的专利申请不能获得授权。经过审理,EPO在2010年6月10日宣告CSIR胜诉。该案中,异议申请
On June 10, 2010, the Indian Council for Scientific and Industrial Research (CSIR) won the Patent Dispute Litigation in the European Patent Office (EPO) and successfully dismissed the authorization of a drug patent application. The patent applicant is one of the most famous pharmaceutical R & D and manufacturing enterprises in China. During the 9-month opposition period after the patent application was filed in 2007 and was authorized by the EPO, the patent application was challenged by the CSIR. According to the opponents, the relevant Medicines have been used in India for more than 1,500 BC. Published evidence in the 9th century AD demonstrated that India has made public use of the technology and that patent applications from China can not be authorized. After trial, the EPO declared the CSIR victory on June 10, 2010. In the case, the opposition application